Year in Review: Psoriatic Arthritis
The year 2021 saw additional advances and refinements in the treatment of psoriatic arthritis (PsA), a heterogeneous condition that in the past has lagged behind rheumatoid arthritis (RA) in therapeutic progress. But improved understanding of the pathogenesis of PsA has allowed more targeted, safer, and more effective treatment approaches. In particular, data have begun to […]
Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: Study
Latest Arthritis News By Amy Norton HealthDay Reporter TUESDAY, Nov. 9, 2021 (HealthDay News) “Ultra-low” doses of the drug rituximab may be enough to keep some patients’ rheumatoid arthritis under control for several years, a new, preliminary study suggests. Researchers found that among 118 patients, low doses of the drug were comparable to […]
Targeting IL-23 Succeeds in Psoriatic Arthritis
The monoclonal antibody risankizumab (Skyrizi) showed significant efficacy for psoriatic arthritis (PsA) in two phase III randomized trials, a researcher reported. In the KEEPSAKE 1 and 2 trials, 1,407 patients with active PsA were randomly assigned to receive subcutaneous risankizumab, 150 mg, or placebo at baseline and then at weeks 4 and 16. On the […]